Table 1.
Baseline demographic and clinical characteristics of the study cohort.
| All participants (n = 245) | MJ-TS- (n = 90) | MJ+TS- (n = 45) | MJ-TS+ (n = 50) | MJ+TS+ (n = 60) | |
|---|---|---|---|---|---|
| Age, median [IQR] | 53·1 [47·0, 59·4] | 56·8 [47·0, 72·0] | 54·7 [47·6, 59·0] | 53·0 [48·1, 56·9] | 49·1 [44·0, 55·3] |
| Years of follow-up, median [IQR] | 1·5 [0·0, 2·1] | 1·8 [0·0, 2·1] | 1·4 [0·9, 2·2] | 1·6 [0·0, 2·3] | 1·5 [0·8, 2·1] |
| Race | |||||
| White | 133 (54·3) | 56 (62·2) | 27 (60·0) | 18 (36·0) | 32 (53·3) |
| Black | 74 (30·2) | 21 (23·3) | 10 (22·2) | 19 (38·0) | 24 (40·0) |
| Other | 38 (15·5) | 13 (14·4) | 8 (17·8) | 13 (26·0) | 4 (6·7) |
| Male gender | 191 (78·0) | 62 (68·9) | 41 (91·1) | 36 (72·0) | 52 (86·7) |
| Marijuana smoking (years), mean (SD) | – | – | 15·6 (12·2) | – | 14 (12·5) |
| Tobacco smoking | |||||
| Never | 98 (40·0) | 74 (82·2) | 24 (53·3) | – | – |
| Former | 37 (15·1) | 16 (17·8) | 21 (46·7) | – | – |
| Current | 110 (44·9) | – | – | 50 (100) | 60 (100) |
| Tobacco smoking (packs per day), mean (SD) | – | – | – | 0·53 (0·42) | 0·86 (0·41) |
| Tobacco smoking (pack-years), mean (SD)a | – | – | – | 22 (23·8) | 28 (19·8) |
| Cocaine useb | 43 (17·6) | 4 (4·4) | 7 (15·6) | 14 (28·0) | 18 (30·0) |
| Alcohol useb | 107 (43·7) | 23 (25·6) | 21 (46·7) | 19 (38·0) | 44 (73·3) |
| HIV positive | 186 (75·9) | 47 (52·2) | 42 (93·3) | 38 (76·0) | 59 (98·3) |
| Duration of HIV infection (years), median [IQR]c | 16·1 [11·7, 20·3] | 15·8 [11·8, 20·1] | 17·3 [13·1, 20·7] | 13·7 [10·9, 19·1] | 16·8 [11·8, 19·7] |
| CD4+ T-cell count (cells/μL), median [IQR]c | 440 [216, 667] | 440 [272, 659] | 347 [220, 525] | 446 [250, 668] | 473 [205, 708] |
| Plasma viral load <200 copies/mLc | 167 (90·2) | 43 (91·5) | 39 (95·1) | 31 (83·8) | 54 (91·5) |
| White blood cell count (x 109 cells/L), median [IQR] | 5·8 [4·5, 7·3] | 6·0 [4·6, 7·3] | 5·4 [4·3, 6·6] | 5·6 [4·4, 7·6] | 6·1 [4·5, 7·1] |
| Hypertension risk factord | 105 (42·9) | 30 (33·3) | 20 (44·4) | 27 (54·0) | 28 (46·7) |
| Hyperlipidemia risk factord | 63 (25·7) | 20 (22·2) | 12 (26·7) | 16 (32·0) | 15 (25·0) |
| Diabetesd | 31 (12·7) | 13 (14·4) | 5 (11·1) | 8 (16) | 5 (8·3) |
| 2–3 traditional cardiovascular risk factors | 56 (22·9) | 15 (16·7) | 11 (24·4) | 17 (34) | 13 (21·7) |
| Cardiovascular diagnosese | 30 (12·2) | 6 (6·7) | 5 (11·1) | 9 (18·0) | 10 (16·7) |
| COPD diagnosese | 23 (9·4) | 6 (6·7) | 4 (8·9) | 8 (16·0) | 5 (8·3) |
All data are n (%) unless otherwise indicated. Abbreviations: IQR, interquartile range; MJ-TS-, non-smoker; MJ+TS-, marijuana-only smoker; MJ-TS+, tobacco-only smoker; MJ+TS+, dual marijuana-tobacco smoker; SD, standard deviation.
- Estimated number of 20-cigarette packs smoked/day multiplied by years smoked.
- Dependence or abuse, or ≥2 study visits with heavy use (≥14 drinks/week of alcohol, or daily or weekly use of cocaine).
- Calculated for HIV positive participants only.
- ≥2 study visits with medication use for the indicated condition or ≥2 study visits with the following laboratory test values: hypertension, systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg; hyperlipidemia, total cholesterol >240 mg/dL; diabetes, hemoglobin A1C ≥6·5%.
- Diagnoses within 5 years prior to endpoint.